Please login to the form below
rovalpituzumab tesirine
This page shows the latest rovalpituzumab tesirine news and features for those working in and with pharma, biotech and healthcare.
Strike three for Rova-T has AbbVie cutting its losses
Rova-T (rovalpituzumab tesirine) consists of an anti-DLL3 antibody linked to a cancer-killing agent called pyrrolo-benzodiazepine.
Latest news
-
European biosimilars hit AbbVie’s Humira revenues in Q4
The fate of its Rovalpituzumab Tesirine (Rova-T) also hangs in the balance after it failed in a phase 3 trial for small cell lung cancer in December.
-
AbbVie slumps on trial results for would-be blockbuster Rova-T
The fall-off is no surprise given that AbbVie has spent the last few months building up expectations for antibody-drug conjugate Rova-T (rovalpituzumab tesirine), pointing to its blockbuster sales
-
Trial of AbbVie's Rova-T disappoints at ASCO
The antibody drug conjugate (ADC) rovalpituzumab tesirine (Rova-T) achieved a modest improvement in a first-in-man trial in recurrent small cell lung cancer (SCLC), a disease with a notoriously
-
AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal
The acquisition will give AbbVie access to Stemcentrx's pipeline of five drugs in clinical trials, including a lead candidate called rovalpituzumab tesirine (rova-T) for small cell lung cancer (SCLC)
European biosimilars hit AbbVie’s Humira revenues in Q4
AbbVie slumps on trial results for would-be blockbuster Rova-T
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Deal Watch April 2016
Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3.
Deal Watch April 2016
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- OPEN Health Acquires ARK
- Live Webinar: Artificial Intelligence for Improving Patient Outcomes & Operational Efficiency
- CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- AstraZeneca chooses Ireland for $360m manufacturing site
- Building the perfect behaviour-change buffet
No results were found
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
